Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,072,110
  • Shares Outstanding, K 117,737
  • Annual Sales, $ 75,420 K
  • Annual Income, $ -652,170 K
  • 60-Month Beta 1.08
  • Price/Sales 68.33
  • Price/Cash Flow N/A
  • Price/Book 16.02
Trade APLS with:

Options Overview Details

View History
  • Implied Volatility 88.94% ( -0.06%)
  • Historical Volatility 88.67%
  • IV Percentile 75%
  • IV Rank 29.86%
  • IV High 206.70% on 02/16/23
  • IV Low 38.81% on 06/21/23
  • Put/Call Vol Ratio 1.25
  • Today's Volume 457
  • Volume Avg (30-Day) 6,699
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 150,204
  • Open Int (30-Day) 146,192

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -1.22
  • Number of Estimates 10
  • High Estimate -1.03
  • Low Estimate -1.37
  • Prior Year -1.75
  • Growth Rate Est. (year over year) +30.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.54 +10.14%
on 08/29/23
51.54 -15.50%
on 09/19/23
+2.78 (+6.82%)
since 08/25/23
3-Month
19.83 +119.62%
on 08/07/23
92.61 -52.97%
on 06/28/23
-40.89 (-48.42%)
since 06/26/23
52-Week
19.83 +119.62%
on 08/07/23
94.75 -54.04%
on 06/14/23
-15.75 (-26.56%)
since 09/26/22

Most Recent Stories

More News
APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)...

APLS : 43.50 (+0.97%)
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 2, 2023 to file lead plaintiff applications...

APLS : 43.50 (+0.97%)
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

APLS : 43.50 (+0.97%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS). Such...

APLS : 43.50 (+0.97%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action...

APLS : 43.50 (+0.97%)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023

/PRNewswire/ -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action...

APLS : 43.50 (+0.97%)
ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)...

APLS : 43.50 (+0.97%)
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

/PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have...

APLS : 43.50 (+0.97%)
Markets Today: Stocks Slip on Higher Bond Yields and Chip Stock Weakness

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are down -0.08%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are down -0.25%. Stock index futures this morning are mixed. Stock index...

ESZ23 : 4,319.50 (-1.35%)
NQZ23 : 14,727.00 (-1.39%)
ASML : 570.20 (-2.72%)
KLAC : 445.00 (-2.28%)
LRCX : 606.81 (-2.22%)
AMAT : 134.28 (-1.69%)
ADBE : 503.26 (-1.63%)
LNN : 114.74 (-1.60%)
NUE : 151.99 (-2.10%)
DOCU : 40.96 (-1.30%)
DASH : 74.23 (-1.64%)
U : 30.57 (-2.52%)
APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action...

APLS : 43.50 (+0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 47.73
2nd Resistance Point 46.20
1st Resistance Point 44.64
Last Price 43.50
1st Support Level 41.55
2nd Support Level 40.02
3rd Support Level 38.46

See More

52-Week High 94.75
Fibonacci 61.8% 66.13
Fibonacci 50% 57.29
Fibonacci 38.2% 48.45
Last Price 43.50
52-Week Low 19.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar